Comfrey
HerbalPreclinicalAlso known as: Symphytum officinale, Knitbone, Boneset, Bruisewort, Consound, Slippery root, Common comfrey, True comfrey, Blackwort, Ass-ear, Kuhkraut, Beinwell
Comfrey (Symphytum officinale) is one of the most mechanistically interesting — and simultaneously one of the most legally and toxicologically constrained — herbs in traditional European medicine. It is a large, bristly, perennial member of the borage family (Boraginaceae) native to Europe and western Asia, with broad veined leaves and clusters of nodding pink, purple, cream, or lilac tubular flowers.
Overview
At A Glance
Comfrey's mechanism of action splits into two distinct and important domains that must be kept separate: (1) the topical wound-healing, anti-inflammatory, and analgesic mechanisms of the external constituents (allantoin, rosmarinic acid, mucilage, tannins) applied to intact skin …
Mechanism of Action
Comfrey's mechanism of action splits into two distinct and important domains that must be kept separate: (1) the topical wound-healing, anti-inflammatory, and analgesic mechanisms of the external constituents (allantoin, rosmarinic acid, mucilage, tannins) applied to intact skin for short durations, and (2) the hepatotoxic mechanism of pyrrolizidine alkaloids (PAs) activated by hepatic CYP3A4 to reactive pyrroles that alkylate hepatic sinusoidal endothelial DNA and produce sinusoidal obstruction syndrome. These mechanisms are pharmacologically unrelated — the same plant produces both — and the risk-benefit calculus of comfrey use reduces to keeping the topical mechanisms while avoiding the systemic bioactivation that drives the hepatotoxic mechanism. Topical application of standardized low-PA extracts to intact skin accomplishes this separation; oral use, application on broken skin or mucous membranes, high-PA raw-plant preparations, or prolonged repeated exposure does not.
1. Allantoin — the headline topical active for wound healing and granulation. Allantoin is a small ureide (5-ureidohydantoin) present in comfrey roots at 0.5-2% by dry weight. It has an independent pharmaceutical and cosmetic history: purified allantoin is used in multiple OTC topical formulations as a pro-epithelialization, granulation-stimulating, and keratolytic agent at concentrations of 0.5-2%. Mechanistically, allantoin is thought to: (a) stimulate fibroblast proliferation and migration, accelerating granulation tissue formation in healing wounds; (b) promote desquamation of damaged stratum corneum, clearing non-viable skin to permit re-epithelialization; (c) improve keratinocyte proliferation at wound edges; (d) soothe and hydrate the stratum corneum via humectant and keratolytic effects. In topical comfrey preparations, allantoin contributes measurably to the wound-edge healing, anti-bruise, and skin-soothing effects traditionally attributed to comfrey. Importantly, allantoin itself is not toxic at topical doses — the toxicological concerns of comfrey arise from PAs, not from allantoin. Some "comfrey-inspired" topical products use purified allantoin without the comfrey matrix, achieving much of the topical skin-healing benefit with essentially no PA risk.
2. Rosmarinic acid — polyphenolic anti-inflammatory activity. Rosmarinic acid is a caffeic acid ester polyphenol present in multiple medicinal plants including rosemary (Rosmarinus officinalis), lemon balm (Melissa officinalis), sage, and — at lower concentrations — comfrey. It has demonstrated anti-inflammatory effects in vitro and in animal models, including inhibition of complement activation, reduction of leukotriene B4 production, inhibition of lipoxygenase and cyclooxygenase activity, and suppression of NF-κB-dependent inflammatory gene expression. Topically applied rosmarinic acid contributes to the anti-inflammatory component of comfrey's topical effect — reducing edema, erythema, and inflammatory pain in contusions, sprains, and muscle strains. The anti-inflammatory mechanism is broadly shared with curcumin and boswellia topical and systemic anti-inflammatory phytotherapies, though the potency and tissue distribution differ.
3. Mucilaginous polysaccharides — demulcent and barrier effects. Comfrey root contains substantial mucilaginous polysaccharides (complex galactans, arabinogalactans, and related polymers) that produce a thick, slippery gel when mixed with water. Topically, these mucilages provide: (a) a protective barrier film over the skin surface, reducing evaporative water loss and protecting irritated skin from mechanical trauma; (b) mild soothing demulcent effects on irritated tissue; (c) vehicle enhancement for the other actives — the mucilage matrix may promote skin contact and sustained release of allantoin and polyphenolic components. The traditional folk name "slippery root" reflects the characteristic mucilaginous quality. Mucilage alone is not a strong pharmacological actor but contributes to the overall soothing, protective, and film-forming profile of topical comfrey preparations.
4. Tannins — mild astringent and anti-inflammatory. Comfrey contains modest levels of tannins (polyphenolic oligomers and polymers) that produce mild astringent effects on skin contact — constricting superficial blood vessels, reducing weeping of inflamed or damaged tissue, and contributing modestly to anti-inflammatory and antimicrobial activity. The tannin contribution is smaller than in more tannin-rich topical herbs (e.g., witch hazel, oak bark) but is a recognized component of comfrey's overall topical profile.
5. Silicic acid and silica — traditional "bone-healing" chemistry, modest effect. Comfrey hairs and tissues contain appreciable silica and soluble silicic acid derivatives, which some traditional herbalists attribute to its "knitbone" reputation via mineral support of connective tissue. The modern evidence for systemic silicon supplementation in bone or connective tissue health is weak; the topical contribution of silica to comfrey effects is not well-characterized but is unlikely to be major.
6. Choline and phosphatidylcholine — minor. Small amounts of choline and phospholipid components contribute to the aqueous-lipid matrix of the fresh plant but are not substantial pharmacological actors at topical doses.
7. The PA bioactivation pathway — the core hepatotoxic mechanism. The central safety concern of comfrey is the pyrrolizidine alkaloid (PA) hepatotoxicity mechanism. Comfrey contains multiple unsaturated 1,2-pyrrolizidine alkaloids — symphytine, echimidine, lycopsamine, intermedine, symlandine, and corresponding N-oxides — that are absorbed via the GI tract after oral ingestion or (to a much smaller and formulation-dependent extent) via broken skin or mucous membranes after topical exposure. In the liver, these PAs are substrates for CYP3A4 (and to a lesser extent CYP2B6) and are oxidized to reactive pyrroles (dehydropyrrolizidine alkaloid metabolites). These reactive metabolites are electrophilic alkylating agents that covalently bind to DNA, proteins, and actin filaments of hepatic sinusoidal endothelial cells (HSECs). The result is: (a) loss of HSEC integrity and fenestration; (b) swelling and disruption of sinusoids; (c) embolization of HSEC fragments into central venules and small hepatic veins; (d) fibrin deposition and secondary fibrous obliteration of small hepatic veins and sinusoids — producing hepatic sinusoidal obstruction syndrome (SOS / VOD). The clinical picture is painful tender hepatomegaly, weight gain from ascites, jaundice, elevated transaminases, elevated bilirubin, and in severe cases portal hypertension and liver failure. The injury is cumulative and dose-dependent over time — which is why chronic daily oral use is more dangerous than a single exposure, and why the safety framework emphasizes both total lifetime PA exposure and continuous duration of use.
8. The PA N-oxide dynamics. Comfrey PAs are typically present partly as the free alkaloid and partly as the corresponding N-oxides. N-oxides are themselves less hepatotoxic than the free alkaloids but can be reduced back to the free alkaloid in the gut by colonic bacteria (via bacterial reductases) and in the liver — so N-oxide content should not be discounted in the total PA burden calculation. Modern analytical methods for PA content in commercial products typically measure both the free alkaloid and N-oxide fractions and express total PA as a combined figure.
9. The leaf-vs-root distinction. Different plant parts of Symphytum officinale have different PA concentrations. Root content is typically several-fold to tenfold higher than leaf content on a dry-weight basis. Young leaves generally have lower PA content than mature roots. Modern topical products preferentially use leaf-derived extracts or carefully purified root fractions to minimize PA content — this is part of why the commercial low-PA topical products (Kytta-Salbe f, Traumaplant, and similar) are substantially safer than homemade raw-plant preparations.
10. The species question — S. officinale vs S. × uplandicum vs S. asperum. Traditional comfrey is Symphytum officinale (common comfrey). The cultivated hybrid Russian comfrey (Symphytum × uplandicum), used in agriculture as a fast-growing fodder or mulch plant, has a different and generally higher PA profile than S. officinale — including substantial echimidine content — and is considered more toxic. Prickly comfrey (Symphytum asperum) is even higher in PAs. Some "comfrey" commercial plant material historically has been mislabeled or sold as hybrid, contributing to higher-than-expected PA exposure in users of supposedly "common comfrey" products. Reputable modern topical products specify the species and the PA content; homemade or wild-harvested material carries unpredictable species identification and PA burden.
11. Pharmacokinetics of topical absorption on intact skin — low and favorable. The core safety rationale for topical comfrey on intact skin is that percutaneous absorption of PAs through intact stratum corneum is very low. Studies of topical low-PA comfrey preparations have demonstrated that measurable systemic PA exposure from twice-daily application of standard doses over 7-14 days on intact skin is well below the threshold for clinically meaningful hepatic injury based on cumulative PA burden modeling. This safety logic fails if: (a) skin is broken, abraded, ulcerated, or burned — absorption increases dramatically; (b) application is to mucous membranes (oral, genital, rectal) — absorption is much higher; (c) high-PA raw-plant preparations are used; (d) prolonged continuous use beyond the recommended 10-day course; (e) repeated courses totaling >6 weeks per year; (f) concurrent use of CYP3A4-inducing drugs that may accelerate PA bioactivation.
12. The allantoin-PA ratio as a safety marker. Some modern standardized products specify allantoin content (as a marker of the beneficial topical chemistry) and total PA content (as a safety marker) — the goal being to deliver useful topical allantoin and polyphenolic doses while keeping PA content below thresholds. A rough rule of thumb for commercial low-PA topical products is ≤0.35 µg PA per 100 g of ointment, which is thousands of times lower than raw root material.
Mechanism summary. The topical beneficial mechanism — allantoin-mediated epithelialization, rosmarinic acid anti-inflammation, mucilage barrier effect, mild tannin astringency — is legitimate and supports the observed clinical benefit for acute musculoskeletal complaints applied to intact skin. The systemic hepatotoxic mechanism — CYP3A4-mediated bioactivation of PAs to reactive pyrroles that alkylate hepatic sinusoidal endothelium — is what constrains comfrey to topical-only, short-course, intact-skin use. The pharmacology of comfrey is therefore fundamentally about keeping the plant chemistry on the outside of the body while harvesting its topical benefits. Any use pattern that allows meaningful systemic absorption of the PA fraction — oral consumption, mucous membrane exposure, broken-skin application, prolonged high-dose use — crosses the safety threshold regardless of subjective tolerance at the time.
Overview
Comfrey (Symphytum officinale) is one of the most mechanistically interesting — and simultaneously one of the most legally and toxicologically constrained — herbs in traditional European medicine. It is a large, bristly, perennial member of the borage family (Boraginaceae) native to Europe and western Asia, with broad veined leaves and clusters of nodding pink, purple, cream, or lilac tubular flowers. The plant has been used medicinally since classical antiquity — the genus name Symphytum derives from the Greek sympho ("to unite" or "to grow together"), and common names across multiple European languages (knitbone, boneset, bruisewort, beinwell, consound) reflect centuries of traditional use for fractures, sprains, bruises, muscle strains, joint pain, and external wounds. For most of recorded European herbal history, comfrey was used both internally (as teas, decoctions, and poultices applied to mucous membranes) and externally (as poultices, salves, and compresses applied to intact skin). In modern honest practice, only the topical external use of comfrey on intact skin is defensible — and even that use is constrained by specific duration, dose, and formulation rules. The oral use of comfrey is not defensible at any dose, and this entry does not endorse it.
The central safety problem — pyrrolizidine alkaloids. Comfrey contains a class of naturally occurring secondary metabolites called pyrrolizidine alkaloids (PAs) — including symphytine, echimidine, lycopsamine, intermedine, symlandine, 7-acetyl-lycopsamine, and 7-acetyl-intermedine — along with their corresponding N-oxides. These molecules are themselves not acutely hepatotoxic, but they undergo hepatic CYP3A4-mediated bioactivation in the liver to reactive pyrroles (dehydropyrrolizidines) that alkylate hepatic sinusoidal endothelial cells and cause a distinctive, progressive, and sometimes fatal liver injury called hepatic sinusoidal obstruction syndrome (SOS) — formerly known as hepatic veno-occlusive disease (VOD) (Ridker 1985; Stickel 2003; Prakash 1999; Mei 2010). This injury pattern — occlusion of small hepatic veins and sinusoids by fibrous tissue, leading to painful hepatomegaly, ascites, jaundice, portal hypertension, and in severe cases liver failure — has been documented in multiple human case reports of oral comfrey use, in an infant exposed transplacentally to a mother's gordolobo (actually a comfrey-related herb) tea, and in extensive animal experiments (Yeong 1990; Huxtable 1990). The chronic accumulated dose of PAs, not a single high dose, is typically what produces the clinical syndrome — which is why the safety warnings focus on both cumulative total lifetime PA exposure and duration of use, not just maximum daily dose.
FDA action — 2001 oral comfrey ban. In July 2001, the US Food and Drug Administration issued an advisory letter to dietary supplement manufacturers and distributors calling for the removal of oral comfrey-containing products from the US market because of hepatotoxicity concerns. The FDA advisory — while technically a request for voluntary compliance rather than a formal rule — had the effect of removing virtually all oral comfrey products from legitimate commerce in the United States. Similar regulatory actions had already been taken or would shortly be taken in Canada (1989), the United Kingdom (2002), Germany (1992) — where the Commission E initially permitted very limited internal use but subsequently tightened to topical-only — and Australia, New Zealand, and most other developed jurisdictions. The German regulatory posture evolved from a Commission E monograph permitting very small internal doses for short durations to a current regulatory framework permitting only topical application to intact skin, with specified daily total-PA limits (typically ≤1 µg/day for external use, and ≤0.1 µg/day for internal use — internal use now being essentially prohibited for commercial products). The comparative international consensus is therefore clear: oral comfrey is not considered safe at any dose by any major developed-world regulatory agency, and topical comfrey on intact skin is permitted only under narrow formulation and duration constraints. Any product still marketed for oral comfrey use — tea, tincture, capsule, or "traditional" preparation — falls outside the modern international safety consensus. This entry does not treat such marketing as legitimate.
But the topical evidence base is genuinely positive. Despite the catastrophic oral safety profile, topical application of comfrey preparations to intact skin has a credible and growing clinical evidence base for musculoskeletal indications. The Staiger 2012 systematic review (Phytotherapy Research, PMID 22359388) pooled data from ten clinical trials including ankle sprain, muscle pain, knee osteoarthritis, and back pain indications, and concluded that topical comfrey extract formulations produced statistically and clinically meaningful pain relief, improvement in functional status, and reduction in swelling compared to placebo and, in several head-to-head trials, demonstrated non-inferiority or modest superiority versus topical NSAID comparators (diclofenac gel in particular). Key individual trials include Grube 2007 (Phytomedicine) — a 142-subject placebo-controlled RCT of Kytta-Salbe f comfrey ointment for acute ankle sprain showing significantly faster pain reduction and functional recovery; Predel 2005 (Phytomedicine) — a 164-subject placebo-controlled trial of topical comfrey for acute upper or lower back pain; Giannetti 2010 (Advances in Therapy) — topical comfrey for chronic back pain; Grube 2007 for ankle sprain; Koll 2004 (Phytomedicine) — comfrey root extract for ankle sprain; and Kucera 2004 (Advances in Therapy) — topical comfrey for knee osteoarthritis demonstrating functional improvement. These trials were generally conducted with standardized low-PA or PA-reduced topical formulations (discussed in more detail below) and with intact skin application only for short durations (7-14 days typical). The clinical signal is real — but it exists specifically in the context of topical application of low-PA standardized extracts to intact skin for limited durations. It does not generalize to oral use, to high-PA whole-plant preparations, to application on broken skin or open wounds, or to prolonged or repeated courses.
The low-PA or PA-free extracts. Recognizing both the evidence for topical efficacy and the PA hepatotoxicity problem, several European manufacturers developed standardized comfrey extracts with substantially reduced PA content — typically via selective extraction solvents that leave PAs behind or via post-extraction purification steps. The German topical product Kytta-Salbe f (from Merck Selbstmedikation / Procter & Gamble Health) uses a comfrey root fluid extract standardized to contain ≤0.35 µg PAs per 100 g of ointment — thousands of times lower than the PA content of raw comfrey — and is the formulation used in most of the landmark topical RCTs. Traumaplant (Harras-Pharma) uses a fresh-pressed comfrey herb juice (from Symphytum × uplandicum, a related species with different PA profile) prepared to a specified low-PA standard. The regulatory logic of these products is that systemic PA exposure from topical application to intact skin, using standardized low-PA formulations, is below the threshold for cumulative hepatotoxic risk over the durations and exposures studied. This is defensible within those narrow boundaries and has been accepted by European regulators for registered phytomedicines. It is not a license to apply raw comfrey root or homemade high-PA preparations, and it is not a license to apply low-PA preparations to broken skin, mucous membranes, or open wounds — where absorption is substantially higher and unpredictable.
The plant and its chemistry. Symphytum officinale is a rhizomatous perennial 60-120 cm tall with broad lanceolate leaves covered in stiff silica hairs; the root is dark brown to black externally and white and mucilaginous internally. Traditional preparations used both the leaf and the root, but the root contains substantially higher PA concentrations (up to 10× leaf levels) and is accordingly riskier — modern topical products preferentially use leaf or carefully purified root fractions. The topically beneficial phytochemistry includes: (a) allantoin — a small ureide present at 0.5-2% in comfrey roots, long recognized as a pro-epithelialization and granulation-stimulating agent in wound healing research, with its own independent pharmaceutical history (allantoin is included in numerous OTC topical wound-care products and cosmetics at 0.5-2% concentrations); (b) rosmarinic acid — a caffeic acid ester polyphenol with anti-inflammatory and antioxidant activity, shared with rosemary, sage, and other Lamiaceae and Boraginaceae species; (c) mucilaginous polysaccharides — demulcent and film-forming, providing a protective barrier on skin; (d) tannins — astringent, mildly anti-inflammatory; (e) choline and phosphatidylcholine — present in small quantities; (f) triterpenoid saponins and small amounts of silica (from the plant hairs). Comfrey also contains trace vitamin B12 analogs — a frequently cited marketing claim for oral comfrey use that is nutritionally irrelevant at practical doses and does not offset the hepatotoxicity problem.
Related Boraginaceae with shared PA concerns. Comfrey is not the only herb in its family with hepatotoxic PAs. The same class of alkaloids is present in borage (Borago officinalis), coltsfoot (Tussilago farfara), butterbur (Petasites hybridus) — where PA-free standardized extracts have been developed for migraine prevention — hound's-tongue, viper's bugloss, heliotrope, senecio (ragwort) species, and many others. Gordolobo tea mislabeling (where PA-containing senecio is sold instead of the intended Gnaphalium species) was the cause of the infant VOD case mentioned above. Users who understand the comfrey PA issue should recognize that the same concern applies across much of Boraginaceae — which is why orally consumed PA-containing herbs in general are regarded with substantial suspicion by modern regulators.
Who uses topical comfrey responsibly, and why. In modern honest practice, topical comfrey extracts applied to intact skin are a reasonable option for short-duration (≤10 days) symptomatic management of acute musculoskeletal complaints: ankle sprains, muscle strains, acute back pain, contusions, and mild osteoarthritis flares. Athletes and active adults who bruise, sprain, or strain acutely and want a topical anti-inflammatory/analgesic layer find topical comfrey a reasonable alternative or complement to topical NSAIDs (diclofenac gel, ketoprofen gel). The positioning is analogous to how one might use arnica gel, menthol rubs, capsaicin cream, or topical bromelain formulations — as gentle, adjunctive topical anti-inflammatory measures alongside conservative musculoskeletal care (rest, ice, compression, elevation, progressive activity return). Topical comfrey is not a treatment for systemic conditions, internal organ disease, metabolic disease, cancer, infections, fractures (despite the traditional "knitbone" claim, there is no modern evidence that topical comfrey accelerates bone union), or open wound healing requiring medical evaluation.
What comfrey is NOT in modern honest practice. Comfrey is not: (1) an oral tea, capsule, tincture, decoction, or extract — the 2001 FDA ban and equivalent international regulatory actions reflect clear evidence of oral hepatotoxicity; (2) a wound-healing agent for open wounds or broken skin — the absorbed PA dose through broken skin is too high and too unpredictable; (3) a long-term continuous-use topical — cumulative PA exposure drives the risk, and the evidence-supported durations are ≤10 days per course and ≤6 weeks cumulatively per year; (4) a pediatric herb — children <6 years old should not use comfrey topically or orally; (5) a pregnancy or breastfeeding herb — no amount, no route, no duration is acceptable; (6) an internal "blood purifier," "liver tonic," or "tonic for bones" despite traditional herbal marketing — these framings reflect pre-modern herbal theory, not current toxicology; (7) safe in any formulation at any dose if the person has pre-existing liver disease (cirrhosis, chronic hepatitis, prior PA injury, or advanced fatty liver); (8) a substitute for medical evaluation of any significant musculoskeletal injury, persistent pain, or symptom warranting diagnosis.
Summary framing. Comfrey represents one of the clearest cases in modern herbal medicine where traditional use and modern evidence part company. The traditional oral and mucous-membrane use, based on centuries of empirical observation, was genuinely effective for some indications — but was also genuinely hepatotoxic in ways that pre-modern medicine could not attribute to the herb because VOD/SOS is insidious, progressive, and often delayed by months to years. Modern analytical chemistry, toxicology, and pharmacovigilance revealed the mechanism; modern regulators responded appropriately; and the modern defensible use of comfrey is topical application of standardized low-PA extracts to intact skin for short durations, for acute musculoskeletal complaints. Users who want the benefits without the legal and hepatotoxic risks should use commercial low-PA topical products (e.g., Kytta-Salbe f, Traumaplant where available) from reputable European pharmaceutical manufacturers rather than making homemade poultices, teas, or tinctures from raw comfrey. Users who have pre-existing liver disease, who are pregnant or breastfeeding, who have young children, or who require internal use should use alternative anti-inflammatory strategies entirely — boswellia, curcumin, omega-3, devils-claw extract, white willow bark, or conventional NSAIDs under medical supervision. This is educational content and not medical advice; any significant injury, persistent pain, or complicating factor warrants appropriate clinical evaluation rather than self-directed herbal care.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications — NO COMFREY USE WHATSOEVER
Pregnancy — absolute contraindication. Comfrey is absolutely contraindicated in pregnancy for any use, any dose, any duration, any route. Pyrrolizidine alkaloid transplacental exposure can cause fetal hepatotoxicity, neonatal VOD/SOS, and potentially fatal infant liver disease. The Bach 1989 infant gordolobo-tea case is the classic tragic example — an infant developed fatal VOD after maternal consumption of PA-containing herbal tea. Even topical comfrey use on intact skin during pregnancy is not considered safe because residual systemic absorption plus transplacental PA transfer is not acceptable risk during a critical developmental period. Women planning pregnancy should discontinue comfrey use at least several weeks before conception.
Breastfeeding / lactation — absolute contraindication. Pyrrolizidine alkaloids are excreted in breast milk and can cause neonatal VOD in nursing infants. No topical or oral use is acceptable during lactation. Women who have used comfrey before learning of pregnancy or lactation should discontinue immediately and inform their obstetric or pediatric clinician.
Children <6 years old — absolute contraindication. Pediatric hepatic metabolism and developmental vulnerability make children particularly susceptible to PA hepatotoxicity. Children 6-12 may use specific pediatric topical formulations only under medical guidance; younger children should not use comfrey in any form. Accidental ingestion by children is a medical emergency warranting immediate evaluation — keep all comfrey products out of reach.
Pre-existing liver disease — absolute contraindication for internal use and strong relative contraindication for topical use. Patients with any significant liver disease (cirrhosis, chronic hepatitis B or C, autoimmune hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease with fibrosis, prior drug-induced liver injury, prior PA exposure, any cause of portal hypertension) should not use comfrey in any form. The residual risk from even topical low-PA products combined with impaired hepatic reserve is not acceptable when safer alternatives exist.
Known or suspected hypersensitivity to comfrey, Symphytum species, Boraginaceae family plants, allantoin, or any comfrey product excipients — discontinue immediately if allergic symptoms develop; do not retry.
Oral use in any circumstances — absolute contraindication. No oral comfrey tea, tincture, capsule, decoction, or other internal preparation is endorsed in this entry. The FDA 2001 advisory, Canadian 1989 action, UK 2002 restrictions, German regulatory evolution to external-only, Australian restrictions, and equivalent international actions reflect consensus on oral safety that this entry follows.
Application to broken skin, open wounds, ulcers, burns, abrasions, or mucous membranes — absolute contraindication. Percutaneous PA absorption through compromised skin barrier is dramatically higher than through intact skin and is not considered safe. Traditional practice of applying comfrey to open wounds for "wound healing" is specifically contraindicated in modern safe practice. For wound care, use appropriate medical wound-care products under medical guidance.
Relative contraindications — require medical guidance before use
Complex polypharmacy involving hepatically-metabolized drugs: Patients on multiple medications metabolized by CYP3A4, or on known hepatotoxic drugs (amiodarone, methotrexate, isoniazid, valproate, certain statins at high doses, nitrofurantoin, various chemotherapy agents, various TCM herbs with hepatotoxic potential) should discuss comfrey use with their physician or pharmacist. In most cases the recommendation will be to avoid comfrey and use safer topical alternatives (boswellia systemic, topical diclofenac, capsaicin, arnica).
Strong CYP3A4 inducers: Patients on rifampin, phenytoin, carbamazepine, phenobarbital, efavirenz, nevirapine, St. John's wort, or other strong CYP3A4 inducers should avoid comfrey. CYP3A4 induction accelerates PA bioactivation to reactive pyrroles, potentially increasing hepatotoxicity risk even from the residual systemic absorption of topical products.
Heavy alcohol use: Alcohol is an independent hepatotoxin; concurrent heavy alcohol use and comfrey use (even topical) represents additive hepatic insult. Patients with active alcohol use disorder or regular heavy drinking should avoid comfrey.
Concurrent use of other PA-containing herbs: Coltsfoot (Tussilago farfara), borage (Borago officinalis — though borage oil without whole herb may have minimal PA content), butterbur (Petasites hybridus — unless specifically PA-free standardized extract), heliotrope, senecio, crotalaria species, and other Boraginaceae and Asteraceae PA-containing herbs stack with comfrey for total PA exposure. Avoid concurrent use.
Active or recent prior PA exposure: Patients with recent high-dose PA exposure (outbreaks, intentional use of PA-containing herbs, livestock or agricultural occupational exposure) should avoid additional PA exposure regardless of form.
Transplant recipients on immunosuppression (tacrolimus, cyclosporine, sirolimus, mycophenolate): These agents have narrow therapeutic windows and hepatic processing concerns; avoid comfrey.
Active chemotherapy: Oncology patients should avoid any non-essential herbal exposure including topical comfrey unless specifically approved by the oncology team; hepatotoxic potential of chemotherapy stacks unfavorably with any additional hepatic insult.
Patients with concurrent autoimmune hepatitis, primary biliary cholangitis, or other autoimmune liver disease: Avoid.
Prior history of idiosyncratic drug-induced liver injury: Patients with prior DILI from any agent have elevated risk of similar reactions to PA-related metabolites; avoid.
Hereditary or acquired conditions predisposing to hepatic injury: Wilson disease, hemochromatosis with hepatic involvement, alpha-1 antitrypsin deficiency, porphyria, and similar conditions warrant conservative approaches; avoid.
Known mechanical limitations preventing safe topical application: Severe skin breakdown, active dermatitis in potential application area, recent skin grafting, or surgical wound areas should avoid topical application until fully healed.
Bleeding disorders or recent major hemorrhage: Comfrey's direct bleeding risk is small, but liver injury affects coagulation factor synthesis; patients with baseline coagulation concerns should use alternatives.
Planned elective surgery within 7-14 days: Discontinue topical comfrey 7-14 days before elective surgery for general conservative practice — clean baseline LFTs and removal of any residual PA exposure before anesthesia and surgical stress.
Planned blood donation: Although comfrey has not been specifically flagged by blood collection agencies, conservative practice is to avoid recent herbal-medication use before donation; follow collection agency guidance.
Situations warranting medical consultation before any use
- Any history of liver disease of any cause.
- Any current hepatically-processed medication, particularly with hepatotoxic potential.
- Pregnancy, trying to conceive, or breastfeeding.
- Children of any age needing topical musculoskeletal support — alternatives are generally preferred.
- Significant musculoskeletal injury or persistent symptoms — medical evaluation takes precedence over self-directed herbal care.
- Skin conditions in or near the proposed application area.
- Active alcohol use disorder or heavy alcohol consumption.
- Complex medical history involving autoimmune disease, transplant, malignancy, or chronic organ disease.
Symptoms warranting immediate medical attention during or after comfrey use
- Jaundice — yellowing of skin, sclerae (eye whites), mucous membranes.
- Right upper quadrant abdominal pain or tenderness.
- Tender or enlarged liver palpable below the right costal margin.
- Dark urine (cola-colored) or pale stools.
- Unexplained weight gain or abdominal distension (possible ascites from portal hypertension).
- New leg or ankle swelling (possible hepatic or cardiac cause).
- Confusion, disorientation, or somnolence (possible hepatic encephalopathy).
- Gastrointestinal bleeding (black tarry stools, vomiting blood — possible variceal).
- Persistent severe fatigue, anorexia, or nausea out of proportion to other causes.
- Fever with other hepatic symptoms.
- Severe or spreading skin reaction at application site.
- Systemic allergic symptoms (urticaria, wheeze, facial swelling, anaphylaxis) — immediate emergency care.
Do NOT continue comfrey in the presence of any of these symptoms — discontinue, do not reapply, and seek medical evaluation urgently. Bring the product label/container to the medical appointment to facilitate PA exposure assessment.
Legal and regulatory status
-
United States: The FDA issued a July 2001 advisory to supplement manufacturers and distributors calling for removal of oral comfrey products from the market. Topical comfrey products remain legally available as dietary supplements / cosmetics under DSHEA but cannot make disease treatment claims; oral comfrey products have largely exited the legitimate market (some "traditional" or imported products may still be found but are outside mainstream commerce). Commercial low-PA topical products can be obtained via import or specialty retailers.
-
Canada: Health Canada restricted oral comfrey products in 1989; topical products remain available under the Natural Health Products regulations with specific PA limits and labeling requirements.
-
United Kingdom: UK regulators restricted oral comfrey products in 2002; topical products remain available with specifications.
-
Germany: The Commission E monograph originally permitted limited internal use but has evolved to permit only external topical use on intact skin, with specific daily total-PA exposure limits (typically ≤1 µg PA/day for external use, ≤0.1 µg/day for any permitted internal use — though essentially no commercial internal products remain).
-
Australia: The Therapeutic Goods Administration (TGA) has restricted oral comfrey and tightened specifications for topical products.
-
European Union: Various national regulators have generally aligned on external-only use with PA content specifications; the EFSA has issued reports on PA dietary exposure more broadly.
-
Not a CITES concern: Unlike pygeum, there are no endangered species or CITES-related sustainability concerns for comfrey.
Quality variability and the key regulatory concern: The topical comfrey market includes well-regulated European phytomedicines with rigorous PA specifications and less-regulated supplement-market products with variable quality. Consumers should prefer products with explicit PA content disclosure (≤0.35 µg/100 g ointment), allantoin content, GMP manufacturing, and batch analysis availability. Uncharacterized products, "whole-plant" preparations without PA testing, homemade preparations, and any oral comfrey products are outside the modern safety framework.
Not medical advice: This content is educational. Specific use decisions — particularly regarding whether to use topical comfrey at all, duration and frequency of use, management of any concerning symptoms, and interactions with pre-existing medical conditions or other treatments — warrant individualized clinician involvement. Comfrey represents one of the clearest examples in modern herbal medicine where traditional use and modern safety data diverge significantly; respect the modern safety framework and use topical products only within validated limits, or choose alternative approaches entirely.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Comfrey.
Related Compounds
View AllBeta-Sitosterol
HerbalPreclinicalBeta-sitosterol (β-sitosterol) is the most abundant plant sterol in human diets and nature, structurally similar to cholesterol but with an ethyl group addition at C-24 position, making it a phytosterol rather than a zoosterol.
Boswellia
HerbalPreclinicalBoswellia — the aromatic gum resin of the tree Boswellia serrata, known in Ayurvedic tradition as Shallaki or Salai guggul and in English as Indian frankincense — is one of the best-characterized non-NSAID anti-inflammatory botanicals in the modern clinical literature, and one of the few whose mechanism is sufficiently well-understood at the molecular level to justify most of its clinical positioning.
Grape Seed Extract
HerbalPreclinicalGrape Seed Extract (GSE) — the lipid-soluble polyphenol-rich concentrate derived from the seeds of the common wine grape (Vitis vinifera, family Vitaceae) — is one of the most widely sold, most extensively researched, and most commercially heterogeneous botanical antioxidant products in the global supplement market.
Maitake
HerbalPreclinicalMaitake (Grifola frondosa) is a large, fan-shaped polypore fungus native to the temperate hardwood forests of Japan, China, Korea, and parts of northeastern North America and Europe.
Piperine
HerbalPreclinicalPiperine is the pungent alkaloid of black pepper (Piper nigrum) — the compound responsible for pepper's characteristic heat and aroma — and it has become one of the single most important adjuvants in the modern supplement industry not because of any direct clinical effect of its own, but because of its notable ability to increase the oral bioavailability of dozens of co-administered drugs, herbs, and nutrients.
Pygeum
HerbalPreclinicalPygeum (Prunus africana, formerly classified as Pygeum africanum) is a lipophilic bark extract derived from the African cherry tree — a large, slow-growing evergreen hardwood species native to the mountainous forests of sub-Saharan Africa, from Cameroon and Kenya through Uganda, Tanzania, Ethiopia, Madagascar, and south to South Africa.
View Full Dosage Guide →
Protocols, calculator & safety for Comfrey
Research Score
5 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Limited research available
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Is comfrey safe? I keep hearing mixed things.
The short, honest answer: topical comfrey on intact skin with standardized low-PA products for short courses is reasonably safe within strict limits, while oral comfrey is not safe at any dose for anyone in modern practice. The confusion comes from the fact that different authoritative sources are often talking about different use patterns without saying so clearly. Let's untangle. The oral safety problem: Comfrey contains pyrrolizidine alkaloids (PAs) — symphytine, echimidine, lycopsamine, intermedine, and related compounds — that are bioactivated in the liver by CYP3A4 to reactive pyrroles that alkylate hepatic sinusoidal endothelial cells, producing hepatic sinusoidal obstruction syndrome (SOS) — also called veno-occlusive disease (VOD). This injury is progressive, cumulative, and can be fatal. It has been documented in multiple human case reports (Ridker 1985 Gastroenterology PMID 4029902; Weston 1987 BMJ PMID 3103692; Yeong 1990 J Gastroenterol Hepatol PMID 2347008; Stickel 2003 J Hepatol PMID 12794720), demonstrated reproducibly in animal models, and observed in population outbreaks from contaminated grain supplies. In July 2001, the FDA advised removal of oral comfrey products from the US market; Canada, the UK, Germany, Australia, and other developed-world regulators have taken similar actions. The topical safety profile: Modern standardized low-PA topical comfrey products (e.g., Kytta-Salbe f) contain very low PA content (≤0.35 µg per 100 g of ointment), limiting systemic PA absorption through intact skin to levels far below clinically meaningful hepatotoxic thresholds. Clinical trials (Staiger 2012 Phytother Res PMID 22359388; Grube 2007 Phytomedicine PMID 17097870; Predel 2005 Phytomedicine PMID 16194051) have shown these products safe and effective for short-course (7-14 days) topical application to intact skin for acute musculoskeletal complaints. The qualifications that make topical use safe: (1) standardized low-PA product (not homemade raw preparation); (2) intact skin only — no broken skin, open wounds, or mucous membranes; (3) short-course use (≤10-14 days per course); (4) limited annual cumulative use (≤4-6 weeks per year); (5) not in pregnancy, breastfeeding, children <6, or pre-existing liver disease. When these conditions are met, topical comfrey is a reasonable tool for acute musculoskeletal pain management.
Why did the FDA ban oral comfrey in 2001?
In July 2001, the FDA issued an advisory letter to dietary supplement manufacturers recommending the removal of oral comfrey products from the US market because of documented hepatotoxicity risk, specifically sinusoidal obstruction syndrome (VOD) caused by pyrrolizidine alkaloids (PAs). The action was technically a voluntary advisory rather than a formal rule, but had the effect of clearing oral comfrey from legitimate commerce in the United States. The evidence base the FDA relied on included: (1) Human case reports of hepatic VOD attributed to chronic oral comfrey use (Ridker 1985 Gastroenterology PMID 4029902 — a well-documented case of VOD in a chronic comfrey tea consumer; Weston 1987 BMJ PMID 3103692; Yeong 1990 PMID 2347008). (2) Mechanistic understanding of PA hepatotoxicity (Huxtable 1990 Nat Toxins PMID 2197859; Prakash 1999 PMID 10451676; Mei 2010 PMID 20140761) — the pathway of CYP3A4 bioactivation of PAs to reactive pyrroles that alkylate hepatic sinusoidal endothelial DNA, producing sinusoidal destruction and obliteration of small hepatic veins. (3) Extensive animal evidence — reproducible VOD across species (rats, mice, dogs, horses, cattle, nonhuman primates) with oral PA exposure; hepatocellular carcinoma in long-term rodent feeding studies (Hirono and colleagues); livestock economic losses from grazing on PA-containing plants. (4) Population-level PA poisoning outbreaks from contaminated grain supplies (Afghanistan heliotrope-contaminated wheat, India senecio-contaminated flour, Jamaica bush-tea Crotalaria outbreaks) producing mass hepatic VOD and mortality. (5) Parallel international regulatory actions — Canada 1989, Germany Commission E evolution through the 1990s, UK 2002, Australia, and others. The FDA's 2001 advisory was part of this broader international consensus, not a US-specific novel finding. The advisory did not prohibit topical comfrey products, reflecting the different safety calculus for external low-PA standardized products vs oral whole-plant preparations. Oral comfrey products remaining in the US marketplace today are typically either (a) unregulated imports; (b) mislabeled products; (c) products from vendors operating outside the FDA advisory; or (d) traditional herbal preparations that may still be found in some settings. None of these are endorsed by mainstream regulatory consensus and none are supported by this entry. The practical bottom line: no honest modern practitioner — herbalist, naturopath, medical doctor, pharmacist — endorses oral comfrey use for any indication at any dose. If anyone suggests oral comfrey, seek a different information source.
Does topical comfrey actually work for sprains and sore muscles?
Yes, with real clinical trial evidence specifically for acute musculoskeletal complaints applied to intact skin — this is the one context where comfrey has genuine modern evidence-based endorsement. The landmark evidence synthesis is Staiger 2012 (Phytotherapy Research PMID 22359388), a systematic review pooling data from ten randomized controlled trials of topical comfrey preparations for ankle sprain, back pain, muscle pain, and knee osteoarthritis — concluding that topical comfrey extract produces statistically and clinically meaningful pain relief, improvement in functional status, and reduction in swelling versus placebo, with onset of perceivable benefit within 1-3 hours of first application and peak effect over 3-7 days. Key individual trials: Grube 2007 (Phytomedicine PMID 17097870) — a 142-subject placebo-controlled RCT of Kytta-Salbe f comfrey ointment three times daily for 8 days for acute ankle sprain, showing significantly greater and faster improvement in tenderness, spontaneous pain, and functional impairment versus placebo. Predel 2005 (Phytomedicine PMID 16194051) — 164 patients, placebo-controlled, topical comfrey for acute back muscle pain, significant pain reduction and functional improvement. Giannetti 2010 (Advances in Therapy PMID 21088883) — topical comfrey for acute upper/lower back pain, confirmatory positive findings. Koll 2004 (Phytomedicine PMID 15237765) — ankle sprain with comfrey root extract, significant pain and functional improvement. Kucera 2004 (Advances in Therapy PMID 15724604) — 220-patient placebo-controlled trial of topical comfrey for knee osteoarthritis over 3 weeks showing significant WOMAC pain/stiffness/function improvement. Head-to-head vs topical diclofenac: Several small trials have compared topical comfrey to topical diclofenac gel, showing non-inferiority to modest superiority of comfrey for pain and functional outcomes with comparable local tolerability. The effect size: clinically meaningful pain relief (30-50% reduction in pain scores typical) within the first few days of application for acute injury, developing further over a 7-14 day course. Caveats to the positive evidence: (1) trials used standardized low-PA commercial formulations, not homemade preparations; (2) application was to intact skin only; (3) trial durations were short (7-21 days typical); (4) trials did not extend beyond 3 weeks of continuous use; (5) the evidence is specific to acute musculoskeletal pain — not neuropathic pain, not fibromyalgia, not systemic conditions. Practical positioning: topical comfrey is a legitimate adjunct for acute ankle sprain, muscle strain, localized back pain, contusion, and osteoarthritis flare management — comparable in evidence-tier to topical NSAIDs — used as a short course with all the safety limits respected.
What are pyrrolizidine alkaloids (PAs) and why are they dangerous?
Pyrrolizidine alkaloids (PAs) are a class of naturally occurring nitrogen-containing plant secondary metabolites that are themselves generally not toxic, but are bioactivated in the liver by CYP3A4 into reactive pyrroles that covalently bind to and damage hepatic sinusoidal endothelial cells, producing the distinctive liver injury called sinusoidal obstruction syndrome (SOS) — formerly known as veno-occlusive disease (VOD). The chemistry: PAs share a common pyrrolizidine nucleus (a fused bicyclic ring with nitrogen) with various ester or acyl substitutions. The toxic PAs are those with a 1,2-unsaturated pyrrolizidine nucleus — these can be oxidized to the reactive dehydropyrrolizidine (pyrrole) form. Saturated PAs (without the 1,2 double bond) are much less toxic. Comfrey PAs include symphytine, echimidine, lycopsamine, intermedine, symlandine, 7-acetyl-lycopsamine, and 7-acetyl-intermedine, plus corresponding N-oxides (which can be reduced back to the free alkaloid by colonic bacteria or hepatic reductases). The mechanism of hepatotoxicity (Huxtable 1990 PMID 2197859; Mei 2010 PMID 20140761; Prakash 1999 PMID 10451676): (1) PA is absorbed and reaches the liver; (2) CYP3A4 (and to a lesser extent CYP2B6) oxidizes the PA to a reactive pyrrole metabolite; (3) the reactive pyrrole alkylates DNA, proteins, and cytoskeletal actin of hepatic sinusoidal endothelial cells (HSECs); (4) HSECs swell, lose integrity, and slough into the sinusoidal space; (5) sinusoidal obstruction, central venule fibrosis, and progressive small-hepatic-vein occlusion ensue; (6) clinical consequences include painful hepatomegaly, ascites, jaundice, portal hypertension, and potentially liver failure. The cumulative nature: the injury is dose- and time-dependent — chronic low-dose exposure over months is typically more dangerous than a single high-dose exposure, though both can cause the syndrome. This is why the safety framework focuses on cumulative lifetime PA exposure and total duration of use, not just single-dose toxicity. Beyond comfrey: PAs are present in multiple herbal products — coltsfoot (Tussilago farfara), borage (Borago officinalis, especially whole herb; borage oil has minimal PA content), butterbur (Petasites hybridus, PA-free standardized extracts developed for migraine), hound's-tongue, viper's bugloss, heliotrope (Heliotropium species), senecio/ragwort species, crotalaria species. PA contamination of honey (from bees foraging on PA-containing plants) and of wheat or other grains (field contamination) is a recognized food-safety concern. Regulatory context: multiple regulatory agencies have classified certain PAs as probable human carcinogens (IARC Group 2B for some); the European Medicines Agency and EFSA have set daily PA exposure limits for herbal products (typically <1 µg/day for external use, <0.1 µg/day for any permitted internal use, with practical ceilings much lower for most commercial applications). Practical meaning for users: the PA hepatotoxicity mechanism is well-characterized, reproducible across species, and supported by human case reports; avoiding oral PA-containing herbs and limiting topical exposure to standardized low-PA products for short durations are appropriate safety measures.
Can I use comfrey for wound healing on a cut or open injury?
No — modern safety guidance specifically contraindicates applying comfrey to broken skin, open wounds, cuts, ulcers, or burns. This is an important distinction from traditional herbal practice, which historically used comfrey poultices directly on wounds because of the observed wound-healing effect from allantoin and other constituents. The reason modern guidance restricts to intact skin only is that percutaneous absorption of pyrrolizidine alkaloids (PAs) through intact stratum corneum is very low, but absorption through broken, abraded, ulcerated, or burned skin is dramatically higher and approaches oral absorption in magnitude. This means the systemic PA exposure from application to an open wound can reach levels capable of causing hepatotoxicity (VOD/SOS), even though the local wound area is small. The traditional observation of faster wound healing with topical comfrey reflects allantoin-mediated fibroblast proliferation, granulation tissue stimulation, and anti-inflammatory effects — real and biologically interesting — but the delivery mechanism (direct application to the wound) also delivers PAs at unsafe levels for the hepatic risk. Modern alternatives for wound healing: (1) For minor cuts, abrasions, scrapes: standard wound care — clean with soap and water, antiseptic if appropriate, clean dry dressing, monitor for infection; purified allantoin-containing OTC products (at 0.5-2% concentration) can be used directly on wound beds for their pro-epithelialization effect without the comfrey PA risk. (2) For more significant wounds: medical evaluation is appropriate; appropriate wound dressings (hydrocolloid, hydrogel, foam, etc.) per clinical context; topical antibiotics if indicated; no comfrey. (3) For post-surgical wounds: follow surgical team instructions; comfrey should not be applied to surgical incisions until fully closed and re-epithelialized (typically 2-4 weeks post-op minimum, with surgeon approval) — and even then, application over fully-closed intact skin for residual bruising or soft-tissue soreness rather than on the healing incision itself. (4) For chronic wounds, ulcers, or non-healing wounds: medical evaluation — non-healing wounds often have underlying pathology (vascular, diabetic, pressure, infectious, malignant) requiring specific management, not herbal self-care. What about after the wound has fully closed? Once a wound is fully re-epithelialized (intact skin, no broken areas, full barrier function restored), topical comfrey can be used over the area for soft-tissue soreness of adjacent muscles or joints per standard topical comfrey guidelines — but should not be used on the scar itself for 'scar softening' or 'scar reduction' purposes (that's different from bona fide musculoskeletal indications, and evidence for scar-specific effects of comfrey is limited). Summary: modern comfrey use is specifically topical-on-intact-skin-only; the traditional wound-application is one of the practices that does not translate to modern safety standards, and it should not be used.
How is comfrey different from arnica for bruising and muscle pain?
Both are topical herbal anti-inflammatories with real trial evidence for acute musculoskeletal complaints, but they have different phytochemistry, different safety profiles, and somewhat different best-use contexts. Comfrey (Symphytum officinale) is a Boraginaceae family plant with allantoin, rosmarinic acid, mucilaginous polysaccharides, tannins, and — importantly — pyrrolizidine alkaloids (PAs) that drive the main safety concerns. Arnica (Arnica montana) is an Asteraceae family plant with sesquiterpene lactones (helenalin, dihydrohelenalin), flavonoids, phenolic acids, and essential oils providing anti-inflammatory and analgesic effects. Evidence: both have systematic-review evidence for topical application in acute musculoskeletal injury (sprain, strain, contusion, osteoarthritis). Topical arnica has been studied in osteoarthritis trials (showing modest benefit), post-surgical bruising/ecchymosis trials (mixed results), and acute soft-tissue injury trials. Topical comfrey has more robust RCT evidence specifically for ankle sprain and back pain (Grube 2007 PMID 17097870, Predel 2005 PMID 16194051, Giannetti 2010 PMID 21088883) and for knee osteoarthritis (Kucera 2004 PMID 15724604), synthesized by Staiger 2012 (PMID 22359388). Safety differences: (1) Comfrey has the PA hepatotoxicity concern — mandatory intact-skin-only application, short-course duration limits, and cumulative annual exposure limits. (2) Arnica has different safety considerations — sesquiterpene lactones can cause contact dermatitis, especially with prolonged use; oral homeopathic arnica (which is pharmacologically inert at typical dilutions) is a different product from topical arnica gel/cream; topical arnica should still not be applied to broken skin or mucous membranes, but does not carry the same hepatotoxic cumulative concern as comfrey PAs. (3) Allergic/hypersensitivity to Asteraceae family plants (chamomile, marigold, feverfew, ragweed) can produce cross-reactivity to arnica; Boraginaceae family cross-reactivity is less commonly noted for comfrey. Best-use contexts: (1) Acute superficial bruising — both are reasonable; arnica has a stronger traditional reputation for bruises specifically and some direct trial evidence for post-surgical ecchymosis; can alternate or use on different skin zones. (2) Acute sprain/strain with deeper musculoskeletal involvement — comfrey has the more robust ankle-sprain and back-pain evidence; reasonable first choice within the safety envelope. (3) Chronic knee osteoarthritis symptomatic flare — both have some evidence; comfrey slightly better-characterized in trials; rotation with topical NSAIDs and capsaicin is the standard approach. (4) Post-operative bruising on fully-closed incisions — arnica (or allantoin-containing products) may be reasonable once wound is fully closed; comfrey is traditionally not used this way and the allantoin alternative captures much of the benefit without the PA issue. (5) Hypersensitivity to either family — cross to the other class if allergic to one. Practical combined use: using comfrey and arnica together on adjacent but not overlapping skin zones for a significant sprain+bruise injury is reasonable — for example, comfrey ointment on the ankle joint proper where the sprain is, arnica gel on the broader bruise extending up the calf and foot — each at standard doses, respecting cumulative duration limits for comfrey, monitoring for skin tolerability. Don't layer both on the exact same skin patch simultaneously (vehicle incompatibility and additive irritation risk).
What are safer oral herbal alternatives for the indications people used comfrey for?
Several well-studied herbs and nutrients provide the systemic anti-inflammatory and musculoskeletal-support benefits that traditional oral comfrey was sought for, with meaningfully better safety profiles and no pyrrolizidine alkaloid concern. The key insight is that much of what traditional oral comfrey was claimed to do — generalized anti-inflammatory support, joint and connective tissue effects, "knitbone" effects — can be addressed by other oral phytotherapies and nutrients without the PA hepatotoxicity risk. For generalized systemic anti-inflammatory support: (1) Curcumin (from turmeric, Curcuma longa) 1000-2000 mg/day with piperine (from black pepper) 5-20 mg to enhance bioavailability — extensive RCT evidence for osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, and systemic inflammation (Daily 2016 meta-analysis, PMID 27533649; Hewlings 2017 review, PMID 29065496); favorable safety profile; the bioavailability issue requires good formulation (piperine, lecithin, micronized forms). (2) Boswellia serrata extract standardized to AKBA (acetyl-11-keto-β-boswellic acid) 300-500 mg two to three times daily — RCT evidence for osteoarthritis of the knee (Kimmatkar 2003, PMID 12622457; Sengupta 2008, PMID 18667054); 5-lipoxygenase/leukotriene pathway inhibition; favorable safety profile. (3) Omega-3 fatty acids (EPA + DHA) 2-3 g/day — inflammation resolution via specialized pro-resolving mediators (resolvins, protectins, maresins) (Serhan 2014, PMID 24625929); extensive evidence for cardiovascular benefit, some evidence for joint inflammation and rheumatoid arthritis symptom management; favorable safety profile. For joint and connective tissue support: (4) Devils-claw (Harpagophytum procumbens) 600-1200 mg standardized extract daily — RCT evidence for low back pain and osteoarthritis (Gagnier 2007 Cochrane review, PMID 17253491; Chrubasik 2002, PMID 12040876); harpagoside is the primary active; generally well-tolerated. (5) White willow bark (salicin-containing) 240 mg salicin/day — traditional salicylate-based anti-inflammatory; caveats regarding salicylate sensitivity; safer than synthetic aspirin in some traditional framings but shares salicylate mechanism. (6) Glucosamine and chondroitin sulfate at standard doses — modest symptomatic benefit in some OA trials; favorable safety. (7) Collagen peptides or type II collagen — some evidence for OA symptomatic support. For "knitbone" / bone-healing claims (now recognized as insufficiently supported): (8) Adequate calcium, vitamin D, vitamin K2, magnesium, and protein intake — evidence-based bone nutrition; comfrey was traditionally thought to aid bone healing via silica and allantoin but modern evidence does not support this specific claim. (9) Appropriate orthopedic evaluation and immobilization for any suspected fracture — no herbal replaces appropriate fracture care. For general "liver tonic" or "tonic herb" framing (pre-modern concept): (10) Milk thistle (Silybum marianum, silymarin) — favorable safety profile; evidence mixed but generally positive for supportive hepatic use; extensively used in European hepatology. (11) Avoiding hepatic toxins — alcohol, unnecessary medications, hepatotoxic herbs, high-dose acetaminophen — is more impactful than any "tonic" herb. For wound healing specifically: (12) Purified allantoin in commercial topical products at 0.5-2% — provides the allantoin-mediated wound healing benefit without PA exposure. (13) Honey dressings for appropriate wounds — antimicrobial and pro-healing with established evidence in specific wound-care contexts. (14) Appropriate modern wound care — the evidence-based alternative to traditional comfrey poultices. Summary: the indications people sought oral comfrey for are all addressable by evidence-based alternatives with better safety. If you have been using oral comfrey for any reason, switch to one of these alternatives tailored to your specific goal — and consider medical evaluation if symptoms warrant diagnosis rather than self-directed herbal management.
What is veno-occlusive disease (VOD) / sinusoidal obstruction syndrome (SOS)?
Hepatic veno-occlusive disease (VOD), now more commonly called sinusoidal obstruction syndrome (SOS), is a distinctive form of liver injury caused by toxic damage to hepatic sinusoidal endothelial cells (HSECs) with progressive fibrous occlusion of hepatic sinusoids and small central hepatic veins, producing painful hepatomegaly, ascites, jaundice, portal hypertension, and in severe cases liver failure. The terminology has evolved: older literature uses "veno-occlusive disease" reflecting the eventual small-hepatic-vein fibrosis; more recent literature prefers "sinusoidal obstruction syndrome" reflecting the primary pathology at the sinusoid/HSEC level. Both terms describe the same entity. Causes: (1) Pyrrolizidine alkaloid (PA) exposure — from comfrey, coltsfoot, borage, heliotrope, senecio/ragwort, crotalaria, and other PA-containing herbs (the comfrey-specific concern this entry addresses). (2) Hematopoietic stem cell transplant (HSCT) conditioning regimens — particularly busulfan-based regimens; the most common modern cause of SOS in high-income countries. (3) Certain chemotherapy agents — oxaliplatin, gemtuzumab ozogamicin, cytoxan/cyclophosphamide at high doses. (4) Chronic hepatic irradiation. (5) Radio-contaminated grain and environmental PA outbreaks (Afghanistan 1970s heliotrope; India senecio; Jamaica Crotalaria). Pathophysiology: (1) Toxic insult (most relevantly here, the reactive pyrrole metabolite of PAs) alkylates HSEC DNA, proteins, and cytoskeletal elements. (2) HSECs swell, lose fenestration, and slough into the sinusoidal lumen. (3) Red blood cells and cellular debris embolize into central venules, causing functional obstruction. (4) Secondary fibrin deposition and fibrous obliteration of small hepatic veins ensues over weeks to months. (5) Portal hypertension, ascites, hepatomegaly, and if severe enough, hepatic failure develop. Clinical presentation: (a) Acute/subacute onset over days to weeks (typically) of right upper quadrant pain, tender hepatomegaly, weight gain from fluid retention, ascites, jaundice, elevated transaminases, elevated bilirubin, elevated alkaline phosphatase. (b) Progressive chronic form develops over months to years in low-dose chronic exposure — insidious hepatomegaly, gradual liver dysfunction, progression to cirrhosis-like features in severe chronic exposure. (c) Severe/fulminant form with rapid multi-organ failure in catastrophic exposures. Diagnosis: (1) Clinical suspicion based on exposure history and typical presentation. (2) Baltimore or modified Seattle criteria (developed for HSCT-related SOS) — jaundice + tender hepatomegaly or RUQ pain + weight gain >2-5%. (3) Imaging — right upper quadrant ultrasound showing hepatomegaly, ascites, reversed portal vein flow in severe cases; MRI/MRE for fibrosis assessment. (4) Liver biopsy is definitive — showing sinusoidal endothelial injury, central venule fibrosis, hepatocyte zone 3 necrosis — but is invasive and often avoided if clinical picture is clear. (5) Elevated PAI-1, decreased protein C, elevated D-dimer — supportive lab patterns in HSCT-SOS; less established in PA-related SOS. Management: (1) Removing the toxic exposure — discontinuing the offending agent (comfrey, other PA herb, causative drug). (2) Supportive care — fluid/electrolyte management, diuretics for ascites (with caution — overly aggressive diuresis can worsen renal function), paracentesis for symptomatic ascites. (3) Defibrotide — a specific anti-thrombotic/endothelial-stabilizing agent, FDA-approved for severe HSCT-related SOS; role in PA-related SOS is less established. (4) Liver transplantation — for end-stage disease; challenging because of systemic residual PA burden concerns. (5) Symptomatic management — as for any progressive liver disease. Prognosis: Variable and dependent on severity. Mild subacute forms may resolve with supportive care; severe forms have 20-50% mortality; survivors may have residual chronic liver disease, portal hypertension, and long-term complications. Why this matters for comfrey users: chronic oral comfrey exposure can produce the progressive chronic form over months to years, with insidious onset that may be well-established before clinical recognition. Even topical comfrey, if used outside the safety envelope (broken skin, prolonged daily use over years), could theoretically contribute to cumulative PA burden. The safety framework of ≤10-14 days per course, ≤4-6 weeks/year cumulative topical use, intact skin only, standardized low-PA products is designed to keep cumulative exposure well below SOS-causing thresholds. Any person with any oral comfrey exposure or topical comfrey exposure outside the safety envelope who develops any symptoms of liver dysfunction should seek medical evaluation specifically mentioning the comfrey exposure — SOS is diagnosable if suspected but can be missed if the exposure is not disclosed.
Can topical comfrey help with knee osteoarthritis?
Yes, with direct clinical trial evidence supporting modest but meaningful symptomatic benefit for knee osteoarthritis when used as a topical adjunct within the standard safety envelope. The key trial is Kucera 2004 (Advances in Therapy PMID 15724604) — a 220-patient placebo-controlled, double-blind randomized trial of topical comfrey ointment (Kytta-Salbe f) applied three times daily for 3 weeks for symptomatic knee osteoarthritis. Results: significant improvement in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) total score, pain subscore, stiffness subscore, and function subscore versus placebo. Local tolerability was good; no significant hepatic or systemic safety signals within the 3-week trial duration. Staiger 2013 (Phytotherapy Research PMID 23132677) extended the evidence with another placebo-controlled knee OA trial confirming sustained benefit over 3 weeks. Staiger 2012 systematic review (PMID 22359388) included these and pooled with other topical comfrey trials, concluding clinically meaningful pain relief and functional improvement. Practical approach for knee OA symptomatic management: (1) Apply standardized low-PA topical comfrey ointment (Kytta-Salbe f or equivalent) three times daily to intact skin over the symptomatic knee joint; (2) use for 10-14 days per course (up to 3 weeks per the Kucera trial protocol); (3) discontinue and rotate to alternative topicals (diclofenac gel, capsaicin cream 0.025%, menthol rub) or rest period; (4) return to topical comfrey for the next flare, respecting the ≤6 weeks/year cumulative annual limit. Combination with systemic approach: (a) Oral curcumin + piperine for systemic anti-inflammation; (b) boswellia AKBA-standardized extract; (c) omega-3 for long-term anti-inflammatory tone; (d) weight management (strongly evidence-based for knee OA symptomatic improvement); (e) physical therapy with quadriceps strengthening; (f) appropriate use of oral NSAIDs under physician guidance; (g) intra-articular corticosteroid injections for severe flares; (h) hyaluronic acid injections in selected patients; (i) ultimately, orthopedic evaluation for joint replacement when warranted. Comparison to topical NSAIDs: Topical diclofenac gel and other topical NSAIDs have the most robust evidence base for knee OA topical therapy (extensive RCTs, meta-analyses, clinical guideline endorsement). Topical comfrey is a reasonable alternative or rotation partner with comparable efficacy per head-to-head trials and different mechanism. Caveats specific to knee OA: (1) the condition is typically chronic and progressive; topical comfrey is symptomatic, not disease-modifying; (2) cumulative annual use must be tracked since knee OA is a long-term condition requiring long-term management; (3) do not apply to any broken skin (post-injection sites, abrasions); (4) concomitant oral NSAIDs require attention to combined GI, cardiovascular, and renal risks from the NSAID component (not from comfrey itself). Limitations of the evidence: trial durations have been 3 weeks; longer-term continuous use is not well-studied; real-world chronic OA management requires rotation strategies rather than indefinite continuous topical comfrey. Bottom line: topical comfrey is an evidence-supported modest-benefit tool within a multi-modal knee OA symptomatic management toolkit, used in short courses rotating with other topicals and alongside systemic and behavioral approaches — not a standalone or long-term-continuous therapy.
Can children use topical comfrey for bruises or sprains?
No — modern safety guidance specifically contraindicates comfrey use in children under 6, and for older children (6-12) recommends use only with specific pediatric formulations under medical guidance; adolescents (12+) can use adult protocols with adult limits, but safer alternatives are generally preferable for pediatric use. The reason children are treated more conservatively: (1) Developmental hepatic vulnerability — pediatric liver is still developing; susceptibility to toxic insults may be higher than in adults for some mechanisms; (2) Higher body-surface-area-to-weight ratio — for a given topical dose per unit area, children absorb more per kg of body weight than adults, increasing effective systemic PA exposure per kg; (3) Thinner stratum corneum — pediatric skin has lower barrier function, potentially increasing percutaneous PA absorption; (4) Smaller total body mass for clearance — even low PA absorption produces higher blood levels per kg in small bodies; (5) Longer lifetime exposure window — cumulative lifetime PA exposure matters for carcinogenicity concerns; starting PA exposure in childhood extends the lifetime burden; (6) Unknown safety — specific pediatric clinical trial data on topical comfrey are limited; the validated safety envelope in adults should not be extrapolated without data. Regulatory positions: Most European regulatory frameworks include pediatric age restrictions on topical comfrey products (varying by jurisdiction, typically <3, <6, or <12 years); product labeling usually specifies age restrictions. Safer alternatives for pediatric musculoskeletal complaints: (1) Rest, ice, compression, elevation (RICE) for acute sprains and strains — first-line, no medication or supplement needed for most minor pediatric injuries. (2) Age-appropriate oral analgesics per pediatric guidance — acetaminophen or ibuprofen at pediatric doses for short courses. (3) Topical counter-irritants in pediatric-safe formulations — some low-concentration menthol rubs are labeled for pediatric use per specific product. (4) Pediatric orthopedic or sports medicine evaluation for significant injury — children and adolescents with athletic injuries benefit from specialist evaluation. (5) Physical therapy for rehabilitation of significant injury. (6) Topical arnica gel in age-appropriate formulations — has more pediatric-use precedent than comfrey in many European markets, still with age restrictions and short-duration guidance. The underlying principle: comfrey is not a uniquely valuable tool for pediatric musculoskeletal care, and the risk-benefit calculus in children is less favorable than in adults. Use alternatives. If a specific clinical situation arises where a pediatrician or pediatric orthopedist recommends topical comfrey for a child, follow their specific guidance — but this would be an unusual specialist recommendation, not a general-practice recommendation. The default for pediatric musculoskeletal care is conventional medical management, not herbal self-care with agents that have pediatric safety concerns.
Research Tools
Related Compounds
View AllBeta-Sitosterol
HerbalPreclinicalBeta-sitosterol (β-sitosterol) is the most abundant plant sterol in human diets and nature, structurally similar to cholesterol but with an ethyl group addition at C-24 position, making it a phytosterol rather than a zoosterol.
Boswellia
HerbalPreclinicalBoswellia — the aromatic gum resin of the tree Boswellia serrata, known in Ayurvedic tradition as Shallaki or Salai guggul and in English as Indian frankincense — is one of the best-characterized non-NSAID anti-inflammatory botanicals in the modern clinical literature, and one of the few whose mechanism is sufficiently well-understood at the molecular level to justify most of its clinical positioning.
Grape Seed Extract
HerbalPreclinicalGrape Seed Extract (GSE) — the lipid-soluble polyphenol-rich concentrate derived from the seeds of the common wine grape (Vitis vinifera, family Vitaceae) — is one of the most widely sold, most extensively researched, and most commercially heterogeneous botanical antioxidant products in the global supplement market.
Maitake
HerbalPreclinicalMaitake (Grifola frondosa) is a large, fan-shaped polypore fungus native to the temperate hardwood forests of Japan, China, Korea, and parts of northeastern North America and Europe.
Piperine
HerbalPreclinicalPiperine is the pungent alkaloid of black pepper (Piper nigrum) — the compound responsible for pepper's characteristic heat and aroma — and it has become one of the single most important adjuvants in the modern supplement industry not because of any direct clinical effect of its own, but because of its notable ability to increase the oral bioavailability of dozens of co-administered drugs, herbs, and nutrients.
Pygeum
HerbalPreclinicalPygeum (Prunus africana, formerly classified as Pygeum africanum) is a lipophilic bark extract derived from the African cherry tree — a large, slow-growing evergreen hardwood species native to the mountainous forests of sub-Saharan Africa, from Cameroon and Kenya through Uganda, Tanzania, Ethiopia, Madagascar, and south to South Africa.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
